comprehensive -WSS

comprehensive

author：focus 2025-09-27 19:28:28 - browse：8991

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Microsoft's Peter Lee: Generative AI could help doctors be more human

WSS

White House drug shortage group privately met with industry

TytoCare raises $49 million to build out AI

Pregnant women don't need prenatal multivitamins, study concludes

Harvard's David Sinclair gets blowback over aging

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

focus

comprehensive

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Biden calls for immediate release of Niger's president amid apparent coup

BioMarin wins approval for gene therapy to treat hemophilia A

State of the Union pitch: Bigger Medicare drug price negotiations

Jerome Adams on the need for new antivirals for Covid

What Henrietta Lacks settlement says about racism in medicine

Apple is now the first public company to be valued at $3 trillion

Dramatically reducing cancer deaths requires the PASTEUR Act

Novavax promises a turnaround & Lilly roils the obesity market

$1 billion proposal to grow Boston, Massachusetts biotech

hotspot

Dramatically reducing cancer deaths requires the PASTEUR Act

Biden calls for immediate release of Niger's president amid apparent coup

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

What Mike Pence has said that could be used in a Donald Trump trial

What the cancer research community can learn from the Covid response

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

leisure time

explore

hotspot

hotspot